Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | EP300 | Q09472 | 11/20 | 0.43 |
| ▸ | TK1 | P04183 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12261276 | 0.93 | FGFR1 (0.47) | FGFR1SLC22A6EP300TK1CYP2D6 | |
| SCHEMBL3680116 | 0.86 | FGFR1 (0.52) | FGFR1SLC22A6EP300CYP2D6DNMT1 | |
| SCHEMBL23343373 | 0.86 | FGFR1 (0.44) | FGFR1SLC22A6EP300CYP2D6DNMT1 | |
| SCHEMBL27723178 | 0.84 | FGFR1 (0.48) | FGFR1EP300 | |
| SCHEMBL25628523 | 0.84 | FGFR1 (0.48) | FGFR1EP300 | |
| SCHEMBL27977634 | 0.84 | FGFR1 (0.48) | FGFR1EP300 | |
| SCHEMBL13975422 | 0.84 | FGFR1 (0.48) | FGFR1EP300 | |
| SCHEMBL4245808 | 0.84 | FGFR1 (0.48) | FGFR1EP300 | |
| SCHEMBL13596 | 0.84 | FGFR1 (0.43) | FGFR1SLC22A6EP300CYP2D6DNMT1 | |
| SCHEMBL8840764 | 0.83 | FGFR1 (0.41) | FGFR1SLC22A6EP300CYP2D6DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385824-A2 | COMPOUNDS CO-INDUCING CHOLINERGIC UP-REGULATION AND INFLAMMATION DOWN-REGULATION AND USES THEREOF | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2004-02-04 | — | — | EP | disclosed |
| US-20020160988-A1 | Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 2002-10-31 | — | — | US | disclosed |
| WO-2002065977-A2 | COMPOUNDS CO-INDUCING CHOLINERGIC UP-REGULATION AND INFLAMMATION DOWN-REGULATION AND USES THEREOF | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160988-A1 | Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof | CHAT, ACHE, CHRNB2 | FGFR1 4543/4885SLC22A6 3342/4885EP300 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.